WO2020104578A3 - Modulators of free fatty acid receptor 1 and their use for treatment of diseases - Google Patents

Modulators of free fatty acid receptor 1 and their use for treatment of diseases Download PDF

Info

Publication number
WO2020104578A3
WO2020104578A3 PCT/EP2019/082057 EP2019082057W WO2020104578A3 WO 2020104578 A3 WO2020104578 A3 WO 2020104578A3 EP 2019082057 W EP2019082057 W EP 2019082057W WO 2020104578 A3 WO2020104578 A3 WO 2020104578A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
fatty acid
free fatty
modulators
diseases
Prior art date
Application number
PCT/EP2019/082057
Other languages
French (fr)
Other versions
WO2020104578A2 (en
Inventor
Michael LÜCKMANN
Thomas Michael Frimurer
Thue W. Schwartz
Original Assignee
University Of Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Copenhagen filed Critical University Of Copenhagen
Publication of WO2020104578A2 publication Critical patent/WO2020104578A2/en
Publication of WO2020104578A3 publication Critical patent/WO2020104578A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

The present invention relates to the discovery and development of ago-allosteric modulators on the free fatty acid receptor 1 and their use in therapy, particularly their use in the treatment of diabetes.
PCT/EP2019/082057 2018-11-21 2019-11-21 Modulators of free fatty acid receptor 1 and their use for treatment of diseases WO2020104578A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18207521.8 2018-11-21
EP18207521 2018-11-21

Publications (2)

Publication Number Publication Date
WO2020104578A2 WO2020104578A2 (en) 2020-05-28
WO2020104578A3 true WO2020104578A3 (en) 2020-07-23

Family

ID=64650102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/082057 WO2020104578A2 (en) 2018-11-21 2019-11-21 Modulators of free fatty acid receptor 1 and their use for treatment of diseases

Country Status (1)

Country Link
WO (1) WO2020104578A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216330A1 (en) * 2007-10-24 2010-08-11 Astellas Pharma Inc. Oxadiazolidinedione compound
CN106928246A (en) * 2017-03-09 2017-07-07 北京宜生堂医药科技研究有限公司 A kind of compound and preparation method thereof and purposes
CN108033927A (en) * 2017-10-27 2018-05-15 北京宜生堂医药科技研究有限公司 A kind of compound and its preparation method and application
WO2018122775A1 (en) * 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Heteroaryl compounds and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216330A1 (en) * 2007-10-24 2010-08-11 Astellas Pharma Inc. Oxadiazolidinedione compound
WO2018122775A1 (en) * 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CN106928246A (en) * 2017-03-09 2017-07-07 北京宜生堂医药科技研究有限公司 A kind of compound and preparation method thereof and purposes
CN108033927A (en) * 2017-10-27 2018-05-15 北京宜生堂医药科技研究有限公司 A kind of compound and its preparation method and application

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
14 March 2019 (2019-03-14), pages 1 - 21, XP055665086, Retrieved from the Internet <URL:https://www.pnas.org/highwire/filestream/854687/field_highwire_adjunct_files/0/pnas.1811066116.sapp.pdf> [retrieved on 20200204] *
ELEAZU CHINEDUM ET AL: "Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, vol. 289, 25 April 2018 (2018-04-25), pages 32 - 39, XP085398603, ISSN: 0009-2797, DOI: 10.1016/J.CBI.2018.04.026 *
HAN CAO ET AL: "Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate", MOLECULES ONLINE, vol. 22, no. 10, 1 October 2017 (2017-10-01), DE, pages 1752, XP055589736, ISSN: 1433-1373, DOI: 10.3390/molecules22101752 *
MICHAEL LÜCKMANN ET AL: "Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 116, no. 14, 14 March 2019 (2019-03-14), US, pages 7123 - 7128, XP055665079, ISSN: 0027-8424, DOI: 10.1073/pnas.1811066116 *
PARK H ET AL: "Discovery and biological evaluation of novel @a-glucosidase inhibitors with in vivo antidiabetic effect", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 13, 1 July 2008 (2008-07-01), pages 3711 - 3715, XP022716281, ISSN: 0960-894X, [retrieved on 20080520], DOI: 10.1016/J.BMCL.2008.05.056 *

Also Published As

Publication number Publication date
WO2020104578A2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
WO2018190719A3 (en) Anti-sirp alpha antibodies
AU2018284960A1 (en) AADC polynucleotides for the treatment of Parkinson&#39;s disease
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
EA201591403A1 (en) SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
NZ732241A (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PH12019500949A1 (en) Ror-gamma modulators
MY184890A (en) Improved a? protofibril binding antibodies
MY187358A (en) Modified release orally administered amino acid formulations
JOP20210330A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
WO2017066712A3 (en) Modulators of telomere disease
CR20210580A (en) Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
WO2018067520A3 (en) Therapeutic agents and methods:
MX2018008644A (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-deca ne derivatives.
EP3585818A4 (en) Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
WO2017066796A3 (en) Modulators of telomere disease
EP4311575A3 (en) Methotrexate for proliferative vitreoretinopathy
EP3758693A4 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
EP3852774A4 (en) Methods for diagnosis and treatment of type 1 diabetes
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19816212

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19816212

Country of ref document: EP

Kind code of ref document: A2